BioXcel Therapeutics: IGALMI™ Now Approved
Sunday, October 2
11:30 a.m.– 12:15 p.m.
Location: Expert Theater 1
Gary Vilke, MD, FACEP, FAAEM
Please join us for an expert theater about IGALMI, sponsored by BioXcel Therapeutics, inc. IGALMI™ (dexmedetomidine) is the first and only sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose.